Trial · NCT01592370
Results by group318
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 318
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Experienced Drug Related Grade 3-4 AEs | Nivolumab Monotherapy (Expansion) | 19 | Participants | ||
| Number of Participants That Experienced Drug Related Grade 3-4 AEs | Nivolumab + Ipilimumab | 18 | Participants | ||
| Number of Participants That Experienced Drug Related Grade 3-4 AEs | Nivolumab + Lirilumab | 0 | Participants | ||
| Number of Participants That Experienced Drug Related Grade 3-4 SAEs | Nivolumab Monotherapy (Expansion) | 28 | Participants | ||
| Number of Participants That Experienced Drug Related Grade 3-4 SAEs | Nivolumab + Ipilimumab | 8 | Participants | ||
| Number of Participants That Experienced Drug Related Grade 3-4 SAEs | Nivolumab + Lirilumab | 3 | Participants | ||
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab Monotherapy (Expansion) | ALT OR AST > 3XULN | 3 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Ipilimumab | ALT OR AST > 3XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Lirilumab | ALT OR AST > 3XULN | 4 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab Monotherapy (Expansion) | ALT OR AST > 5XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Ipilimumab | ALT OR AST > 5XULN | 0 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Lirilumab | ALT OR AST > 5XULN | 2 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab Monotherapy (Expansion) | ALT OR AST > 10XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Ipilimumab | ALT OR AST > 10XULN | 0 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Lirilumab | ALT OR AST > 10XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab Monotherapy (Expansion) | ALT OR AST > 20XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Ipilimumab | ALT OR AST > 20XULN | 0 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Lirilumab | ALT OR AST > 20XULN | 0 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab Monotherapy (Expansion) | TOTAL BILIRUBIN > 2XULN | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivolumab + Ipilimumab | TOTAL BILIRUBIN > 2XULN | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01592370/results